Transforming growth factor‑β1 and lysophosphatidic acid activate integrin β6 gene promoter in Hep‑3B cells

Xu,Ruirui; Xu,Mingyan; Fu,Yucai; Deng,Xiaoling; Han,Hui; Chen,Xihe; He,Wenjing; Chen,Gengzhen

doi:10.3892/ol.2018.8672

Transforming growth factor‑β1 and lysophosphatidic acid activate integrin β6 gene promoter in Hep‑3B cells

Authors:
- Ruirui Xu
- Mingyan Xu
- Yucai Fu
- Xiaoling Deng
- Hui Han
- Xihe Chen
- Wenjing He
- Gengzhen Chen
View Affiliations

Affiliations: Minimally Invasive Medical Center, The Second Affiliated Hospital of Shantou Medical College, Shantou, Guangdong 515041, P.R. China, Laboratory of Cell Senescence, Shantou University Medical College, Shantou, Guangdong 515041, P.R. China
Published online on: May 8, 2018 https://doi.org/10.3892/ol.2018.8672
Pages: 439-446

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although it is difficult to detect αvβ6 integrin (αvβ6) in normal epithelia cells, its expression is upregulated during wound healing and carcinogenesis. Overexpression of αvβ6 has been demonstrated in epithelial cell carcinomas, such as adenocarcinoma of the colon and ovary. However, the expression of αvβ6 has not been reported in hepatocellular carcinoma (HCC). We previously indicated that LPA may induce αvβ6‑mediated TGF‑β1 signaling mechanisms during the pathogenesis of lung injury and fibrosis. In addition, transforming growth factor‑β1 (TGF‑β1) and lysophosphatidic acid (LPA) have been demonstrated to participate in the progression of HCC. In the present study, we hypothesized that TGF‑β1 and LPA would serve a key role in the subunit integrin β6 (Itgβ6) transcriptional regulatory mechanism in HCC. It was identified that human HCC tissues and Hep‑3B cells expressed Itgβ6. Treatment of Hep‑3B with TGF‑β1 or LPA increased the expression of Itgβ6. Furthermore, truncation experiments indicated a positive regulatory region at ‑326 to ‑157 bp of the Itgβ6 promoter. TGF‑β1 and LPA increased transcriptional activation at this regulatory region. To the best of our knowledge, the present study was the first to demonstrate Itgβ6 expression in HCC, and the data indicate that TGF‑β1 and LPA regulate Itgβ6 expression through the Itgβ6 gene promoter, which is an important factor in the development of HCC.

View Figures

View References

1	Wilson JF: Liver cancer on the rise. Ann Intern Med. 142:1029–1032. 2005. View Article : Google Scholar : PubMed/NCBI
2	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
3	Sherman M: Hepatocellular Carcinoma: Epidemiology, surveillance, and diagnosis. Semin Liver Dis. 30:3–16. 2010. View Article : Google Scholar : PubMed/NCBI
4	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
5	Nordenstedt H, White DL and El-Serag HB: The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 42 Suppl 3:S206–S214. 2010. View Article : Google Scholar : PubMed/NCBI
6	Hynes RO: Integrins: A family of cell surface receptors. Cell. 48:549–554. 1987. View Article : Google Scholar : PubMed/NCBI
7	Giancotti FG and Ruoslahti E: Integrin signaling. Science. 285:1028–1032. 1999. View Article : Google Scholar : PubMed/NCBI
8	Hynes RO: Integrins: Bidirectional, allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
9	Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL and Schuppan D: Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology. 135:660–670. 2008. View Article : Google Scholar : PubMed/NCBI
10	Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura SL, Aldape K, Landers DV, Carpenter W, et al: Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci. 108:2241–2251. 1995.PubMed/NCBI
11	Breuss JM, Gillett N, Lu L, Sheppard D and Pytela R: Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. J Histochem Cytochem. 41:1521–1527. 1993. View Article : Google Scholar : PubMed/NCBI
12	Busk M, Pytela R and Sheppard D: Characterization of the integrin alpha v beta 6 as a fibronectin-binding protein. J Biol Chem. 267:5790–5796. 1992.PubMed/NCBI
13	Yang GY, Xu KS, Pan ZQ, Zhang ZY, Mi YT, Wang JS, Chen R and Niu J: Integrin alpha v beta 6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. Cancer Sci. 99:879–887. 2008. View Article : Google Scholar : PubMed/NCBI
14	Patsenker E, Wilkens L, Banz V, Osterreicher CH, Weimann R, Eisele S, Keogh A, Stroka D, Zimmermann A and Stickel F: The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma. J Hepatol. 52:362–369. 2010. View Article : Google Scholar : PubMed/NCBI
15	Ahmed N, Pansino F, Clyde R, Murthi P, Quinn MA, Rice GE, Agrez MV, Mok S and Baker MS: Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis. 23:237–244. 2002. View Article : Google Scholar : PubMed/NCBI
16	Hecht JL, Dolinski BM, Gardner HA, Violette SM and Weinreb PH: Overexpression of the alphavbeta6 integrin in endometrial cancer. Appl Immunohistochem Mol Morphol. 16:543–547. 2008. View Article : Google Scholar : PubMed/NCBI
17	Zhang ZY, Xu KS, Wang JS, Yang GY, Wang W, Wang JY, Niu WB, Liu EY, Mi YT and Niu J: Integrin alphanvbeta6 acts as a prognostic indicator in gastric carcinoma. Clin Oncol (R Coll Radiol). 20:61–66. 2008. View Article : Google Scholar : PubMed/NCBI
18	Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM and Bromberg J: Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol. 27:4444–4453. 2007. View Article : Google Scholar : PubMed/NCBI
19	Marsh D, Dickinson S, Neill GW, Marshall JF, Hart IR and Thomas GJ: alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. Cancer Res. 68:3295–3303. 2008. View Article : Google Scholar : PubMed/NCBI
20	Xu MY, Porte J, Knox AJ, Weinreb PH, Maher TM, Violette SM, McAnulty RJ, Sheppard D and Jenkins G: Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol. 174:1264–1279. 2009. View Article : Google Scholar : PubMed/NCBI
21	Geng H, Lan R, Singha PK, Gilchrist A, Weinreb PH, Violette SM, Weinberg JM, Saikumar P and Venkatachalam MA: Lysophosphatidic acid increases proximal tubule cell secretion of profibrotic cytokines PDGF-B and CTGF through LPA2- and Gαq-mediated Rho and αvβ6 integrin-dependent activation of TGF-β. Am J Pathol. 181:1236–1249. 2012. View Article : Google Scholar : PubMed/NCBI
22	Wu K, Ding J, Chen C, Sun W, Ning BF, Wen W, Huang L, Han T, Yang W, Wang C, et al: Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology. 56:2255–2267. 2012. View Article : Google Scholar : PubMed/NCBI
23	Balzarini P, Benetti A, Invernici G, Cristini S, Zicari S, Caruso A, Gatta LB, Berenzi A, Imberti L, Zanotti C, et al: Transforming growth factor-beta1 induces microvascular abnormalities through a down-modulation of neural cell adhesion molecule in human hepatocellular carcinoma. Lab Invest. 92:1297–1309. 2012. View Article : Google Scholar : PubMed/NCBI
24	Kitisin K, Ganesan N, Tang Y, Jogunoori W, Volpe EA, Kim SS, Katuri V, Kallakury B, Pishvaian M, Albanese C, et al: Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene. 26:7103–7110. 2007. View Article : Google Scholar : PubMed/NCBI
25	Zhang R, Zhang Z, Pan X, Huang X, Huang Z and Zhang G: ATX-LPA axis induces expression of OPN in hepatic cancer cell SMMC7721. Anat Rec (Hoboken). 294:406–411. 2011. View Article : Google Scholar : PubMed/NCBI
26	Park SY, Jeong KJ, Panupinthu N, Yu S, Lee J, Han JW, Kim JM, Lee JS, Kang J, Park CG, et al: Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene. 30:1351–1359. 2011. View Article : Google Scholar : PubMed/NCBI
27	Mills GB and Moolenaar WH: The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 3:582–591. 2003. View Article : Google Scholar : PubMed/NCBI
28	A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The cancer of the liver Italian program (CLIP) investigators. Hepatology. 28:751–755. 1998. View Article : Google Scholar : PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
30	Knoche K and Kephart D: Cloning blunt-end PfuDNA Polymerase-generated PCR fragments into pGEM^®-T vector systems. Promega Notes. 71:101999.
31	Kuske L, Mensen A, Müllhaupt B, Negro F, Semela D, Moradpour D, Male PJ, Heim MH, Malinverni R, Cerny A and Dufour JF: Swiss Hepatitis C Cohort Study: Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. Swiss Med Wkly. 142:w136512012.PubMed/NCBI
32	Tan YJ: Hepatitis B virus infection and the risk of hepatocellular carcinoma. World J Gastroentero. 17:4853–4857. 2011. View Article : Google Scholar
33	Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettgen P and Mercurio AM: Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest. 115:339–347. 2005. View Article : Google Scholar : PubMed/NCBI
34	Smythe WR, LeBel E, Bavaria JE, Kaiser LR and Albelda SM: Integrin expression in non-small cell carcinoma of the lung. Cancer Metastasis Rev. 14:229–239. 1995. View Article : Google Scholar : PubMed/NCBI
35	Li X, Yang Y, Hu Y, Dang D, Regezi J, Schmidt BL, Atakilit A, Chen B, Ellis D and Ramos DM: Alphavbeta6-Fyn signaling promotes oral cancer progression. J Biol Chem. 278:41646–41653. 2003. View Article : Google Scholar : PubMed/NCBI
36	Thomas GJ, Nyström ML and Marshall JF: Alphavbeta6 integrin in wound healing and cancer of the oral cavity. J Oral Pathol Med. 35:1–10. 2006. View Article : Google Scholar : PubMed/NCBI
37	Ramos DM, Dang D and Sadler S: The role of the integrin alpha v beta6 in regulating the epithelial to mesenchymal transition in oral cancer. Anticancer Res. 29:125–130. 2009.PubMed/NCBI